GlassScriptPhysician profile
Andrew Hararah
NPI 1104920255
$1,594.37
in general payments reported to CMS, 2019-2025
22 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $831 · 2020: $129 · 2021: $22.21 · 2022: $50.97 · 2023: $202 · 2024: $246 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $561.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $434.67 | 2019-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $249.32 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $159.55 | 2019-2023 | Jardiance, Emgality, Mounjaro |
| Amarin Pharma, INC. | $144.60 | 2019-2020 | |
| Corcept Therapeutics | $85.24 | 2024-2025 | Korlym |
| Exact Sciences Corporation | $60.62 | 2024-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.40 | 2019-2020 | |
| Abbvie INC. | $50.42 | 2019 | |
| Abbott Laboratories | $48.58 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Kowa Pharmaceuticals America, INC. | $45.64 | 2019-2020 | |
| Shield Therapeutics INC | $40.36 | 2024 | |
| Renalytix Ai, INC. | $33.71 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Glaxosmithkline, LLC. | $31.44 | 2020-2023 | Trelegy Ellipta |
| Medtronic, INC. | $22.21 | 2021 | |
| Sanofi-Aventis U.S. LLC | $21.24 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $19.86 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.46 | 2019 | |
| Alfasigma USA, INC. | $18.30 | 2020 | |
| Janssen Pharmaceuticals, INC | $16.79 | 2019 | |
| Intuity Medical INC | $15.61 | 2022 | |
| Genentech USA, INC. | $14.28 | 2019 | |
| Merck Sharp & Dohme LLC | $11.07 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Hararah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.